Understanding the Genetic and Hereditary Basis of Atherosclerosis

Sponsor
Wake Forest University Health Sciences (Other)
Overall Status
Completed
CT.gov ID
NCT00344292
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (NIH)
2,763
4
71.1
690.8
9.7

Study Details

Study Description

Brief Summary

Atherosclerosis is a condition that occurs when fatty deposits build up along the inner walls of arteries. New strategies are needed to prevent and treat atherosclerosis. The purpose of this study is to analyze the DNA of participants in two ongoing studies to identify genetic variations responsible for the development of atherosclerosis.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Atherosclerosis is a condition in which deposits of fat, cholesterol, and other substances build up along the inner walls of arteries; these deposits are known as plaque. As plaque builds up, it increases the risk of blood clots, heart attack, and stroke. Research has shown that the risk of developing atherosclerosis can be influenced by heredity. However, researchers have been unable to identify the specific genes associated with this risk. Single nucleotide polymorphisms (SNPs) are small genetic variations that can occur within an individual's DNA. In this study, researchers will analyze the DNA of many individuals for differences in SNP patterns. The goal of the study is to determine which SNP patterns are associated with the development of atherosclerosis. The data from this study may lead to new strategies for early identification of high risk individuals who may benefit from aggressive treatment to prevent the development of atherosclerosis.

    This study will not recruit any new participants. DNA will be collected and analyzed from participants in two existing studies-the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study and the Multi-Ethnic Study of Atherosclerosis (MESA). DNA from the PDAY participants will be obtained from liver samples gathered during an autopsy following the participants' deaths; DNA from the MESA participants will be obtained from blood collected during routine study visits. There will be no additional study visits for participants, and all DNA samples and study information will be kept confidential. Genetic testing will be performed to determine the association between SNPs and subclinical atherosclerosis, which is a form of the condition prior to the onset of symptoms. The study will evaluate specific variations in SNPs and subclinical disease among different ethnic groups, which may help to explain why certain ethnic groups have higher rates of atherosclerosis. The study will also examine the association between SNPs and other indicators of subclinical and clinical atherosclerosis, including the thickness of arteries, heart calcium levels, and blood pressure levels.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    2763 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Retrospective
    Official Title:
    SNPs and Extent of Atherosclerosis (SEA) Study
    Study Start Date :
    Mar 1, 2006
    Actual Primary Completion Date :
    Feb 1, 2012
    Actual Study Completion Date :
    Feb 1, 2012

    Outcome Measures

    Primary Outcome Measures

    1. To estimate the association between common single nucleotide polymorphisms (SNPs) in the human genome and extent of subclinical atherosclerosis among subjects in the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) cohort (N=2,876). [Entire project period.]

    2. To estimate the association between potential atherosclerosis SNPs identified in the PDAY cohort and extent of subclinical atherosclerosis among subjects in the Multi-Ethnic Study of Atherosclerosis (MESA) cohort (N=6,577). [Entire project period]

    3. To define the haplotypic structure of the genome in the regions of SNPs that are associated with atherosclerosis in PDAY and MESA and to perform additional genotyping necessary for haplotype association studies using both the PDAY and MESA cohorts. [Entire project period.]

    4. To disseminate the identity, location, primer sets and allele frequency of the atherosclerosis associated SNPs in PDAY, and those confirmed in MESA, in order to facilitate additional replication and functional studies of the most promising SNPs. [Entire project period.]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    15 Years to 34 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Participant in PDAY or MESA

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Cedars-Sinai Health System Los Angeles California United States 90048
    2 Louisiana State University New Orleans Louisiana United States 70112
    3 The University of Texas Houston Texas United States 77225
    4 University of Washington Seattle Washington United States 98105

    Sponsors and Collaborators

    • Wake Forest University Health Sciences
    • National Heart, Lung, and Blood Institute (NHLBI)

    Investigators

    • Principal Investigator: David M. Herrington, MD, MHS, Wake Forest University Health Sciences

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Wake Forest University Health Sciences
    ClinicalTrials.gov Identifier:
    NCT00344292
    Other Study ID Numbers:
    • 1333
    • U01HL080443-01A1
    • R01 HL080443-01A1
    First Posted:
    Jun 26, 2006
    Last Update Posted:
    Nov 8, 2017
    Last Verified:
    Mar 1, 2017
    Keywords provided by Wake Forest University Health Sciences
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 8, 2017